Stock ADO ANTEOTECH LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials AnteoTech Limited

Equities

ADO

AU000000ADO8

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:05 2024-04-29 am EDT 		5-day change 1st Jan Change
0.022 AUD -4.35% Intraday chart for AnteoTech Limited -4.35% -38.89%
Apr. 08 Anteotech Seeks to Raise AU$6 Million From Share Placement; Shares Fall 26% MT
Mar. 27 AnteoTech Receives AU$1.39 Million from Queensland Critical Minerals and Battery Technology Fund; Shares Down 3% MT

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 17.29 19.39 32.88 497.9 129.2 82
Enterprise Value (EV) 1 13.96 15.11 29.8 477.8 120.1 80.58
P/E ratio -4.74 x -4.64 x -9.8 x -74 x -12 x -6.33 x
Yield - - - - - -
Capitalization / Revenue 17.6 x 70.2 x 26 x 217 x 170 x 224 x
EV / Revenue 14.2 x 54.7 x 23.5 x 208 x 158 x 220 x
EV / EBITDA -5.53 x -4.84 x -10.1 x -79.5 x -11.6 x -8.39 x
EV / FCF 3.33 x -12.5 x -19.9 x -186 x -15.4 x -15.8 x
FCF Yield 30% -7.98% -5.03% -0.54% -6.48% -6.33%
Price to Book 4.32 x 4.58 x 10.4 x 23.6 x 10.5 x 34.5 x
Nbr of stocks (in thousands) 1,152,757 1,491,708 1,644,091 1,952,680 1,987,875 2,049,939
Reference price 2 0.0150 0.0130 0.0200 0.2550 0.0650 0.0400
Announcement Date 9/28/18 8/27/19 8/28/20 8/31/21 8/23/22 8/29/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2018 2019 2020 2021 2022 2023
Net sales 1 0.9813 0.2763 1.266 2.299 0.7609 0.3657
EBITDA 1 -2.525 -3.121 -2.947 -6.013 -10.38 -9.602
EBIT 1 -2.838 -3.308 -3.133 -6.221 -10.72 -10.13
Operating Margin -289.2% -1,197.33% -247.46% -270.54% -1,408.85% -2,770.99%
Earnings before Tax (EBT) 1 -3.385 -3.297 -3.127 -6.216 -10.72 -12.65
Net income 1 -3.636 -3.297 -3.127 -6.216 -10.72 -12.65
Net margin -370.48% -1,193.15% -246.97% -270.33% -1,408.48% -3,460.06%
EPS 2 -0.003162 -0.002800 -0.002040 -0.003447 -0.005422 -0.006317
Free Cash Flow 1 4.192 -1.207 -1.499 -2.566 -7.785 -5.098
FCF margin 427.19% -436.68% -118.42% -111.58% -1,023.18% -1,393.96%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 9/28/18 8/27/19 8/28/20 8/31/21 8/23/22 8/29/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 3.33 4.28 3.08 20.1 9.07 1.41
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 4.19 -1.21 -1.5 -2.57 -7.79 -5.1
ROE (net income / shareholders' equity) -61% -80% -84% -51.1% -64% -172%
ROA (Net income/ Total Assets) -7.05% -44.8% -45.1% -28.2% -34.4% -61.4%
Assets 1 51.53 7.365 6.928 22.05 31.14 20.6
Book Value Per Share 2 0 0 0 0.0100 0.0100 0
Cash Flow per Share 2 0 0 0 0.0100 0.0100 0
Capex 1 0.22 0.08 0.27 0.21 3.12 0.69
Capex / Sales 22.31% 28.31% 21.36% 9.27% 409.79% 188.89%
Announcement Date 9/28/18 8/27/19 8/28/20 8/31/21 8/23/22 8/29/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ANTEOTECH LIMITED Stock AnteoTech Limited
-38.89% 36.13M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+48.32% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ADO Stock
  4. Financials AnteoTech Limited